Clinical Trials
68 trialsNCT06783647 2026-05-18
A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]
Nanjing Leads Biolabs Co.,Ltd
Phase 2 Recruiting
NCT07415031 2026-05-15
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
Mirati Therapeutics Inc.
Phase 2 Recruiting
NCT05631262 2026-05-08
SKB264 Monotherapy in Selected Subjects With Advanced Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 2 Active not recruiting
NCT05083481 2026-05-05
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
Astellas Pharma Inc
Phase 1/2 Active not recruiting
NCT07246863 2026-04-21
Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC
CatalYm GmbH
Phase 2 Recruiting
NCT06741644 2026-04-15
A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors
CStone Pharmaceuticals
Phase 1/2 Recruiting
NCT03917381 2026-04-06
GEN1046 Safety Trial in Patients With Malignant Solid Tumors
Genmab
Phase 1/2 Active not recruiting
NCT05381909 2026-02-20
A Study of BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors
BeOne Medicines
Phase 1 Terminated
NCT07381829 2026-02-02
A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combined With Chemotherapy in Lung Cancer
HC Biopharma Inc.
Phase 1 Recruiting
NCT05867420 2026-01-27
A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.
AskGene Pharma, Inc.
Phase 1/2 Recruiting
NCT06241456 2025-12-09
FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors
Fate Therapeutics
Phase 1 Recruiting
NCT04185883 2025-10-22
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
Amgen
Phase 1 Active not recruiting
NCT06682780 2025-09-25
A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours
LaNova Medicines Limited
Phase 1/2 Recruiting
NCT06947291 2025-09-08
Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 2 Recruiting
NCT05714553 2025-07-18
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
NuCana plc
Phase 1/2 Terminated
NCT05625412 2025-06-13
A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1 Completed
NCT04827576 2025-05-08
ELEVATELung&UC
Gilead Sciences
Phase 2 Terminated
NCT06925659 2025-04-17
A Study of QLM2011 in Subjects With Advanced Solid Tumors
Qilu Pharmaceutical (Hainan) Co., Ltd.
Phase 1 Not yet recruiting
NCT03854227 2025-01-13
A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors
Pfizer
Phase 1 Terminated
NCT04747470 2024-09-03
Study to Assess the Effects of GS-3583 in Participants With Advanced Solid Tumors
Gilead Sciences
Phase 1 Terminated
NCT05148195 2024-03-13
A Phase II Study of Envofolimab and BD0801 With/Without Chemotherapy in Patients With Advanced Solid Tumors
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 2 Terminated
NCT00084734 2023-08-04
Docetaxel, Capecitabine, and Cisplatin in Treating Patients With Advanced Solid Tumors
Roswell Park Cancer Institute
Phase 1 Completed
NCT00357747 2023-08-04
AEG35156 and Docetaxel in Treating Patients With Solid Tumors
Canadian Cancer Trials Group
Phase 1 Completed
NCT00372736 2023-08-04
AEG35156 and Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Solid Tumors
Canadian Cancer Trials Group
Phase 1 Completed
NCT01540253 2022-07-22
PI3K Inhibitor BKM120 and Docetaxel in Treating Patients With Advanced Solid Tumor That is Locally Advanced, Cannot Be Removed By Surgery, or Metastatic
Roswell Park Cancer Institute
Phase 1 Completed
NCT02071862 2022-07-20
Study of the Glutaminase Inhibitor CB-839 in Solid Tumors
Calithera Biosciences, Inc
Phase 1 Completed
NCT04811118 2022-01-31
The Comparison of the Pharmacokinetics of Albumin-bound Docetaxel and Taxotere
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 1 Unknown
NCT04889599 2022-01-11
A Bioequivalence Study of Docetaxel Injection in Patients With Solid Tumours
Zhuhai Beihai Biotech Co., Ltd
Phase 3 Completed
NCT04810208 2021-12-30
Intratumoural Injection of a Novel NanoZolidĀ®-Docetaxel Depot Formulation in Patients With Advanced Solid Tumours
Lidds AB
Phase 1 Terminated
NCT01957007 2020-09-09
A Study of Vantictumab (OMP-18R5) in Combination With Docetaxel in Patients With Previously Treated NSCLC
Mereo BioPharma
Phase 1 Completed
NCT03089645 2020-07-27
MEDI5083 Alone and in Combination With Durvalumab, Tremelimumab, and/or Docetaxel.
MedImmune LLC
Phase 1 Completed
NCT01862328 2020-06-22
Dose Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Combination of Carboplatin and Paclitaxel in Participants With Solid Tumors
Takeda
Phase 1 Completed
NCT04413227 2020-06-02
A Phase Ib Study With Pegylated Recombinant Human Endostatin in Advanced / Metastatic NSCLC or Other Solid Tumors
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1 Unknown
NCT04360317 2020-04-24
Safety of the Combination of SH003 and Docetaxel in Patients With Solid Cancer
Kyunghee University Medical Center
Phase 1 Unknown
NCT02146222 2019-11-18
VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Docetaxel in Treating Patients With Solid Tumors
University of Wisconsin, Madison
Phase 1 Completed
NCT02963168 2019-10-17
A DRF Study to Evaluate Safety, Tolerability, PK, and Activity of Oradoxel Monotherapy in Subjects w Adv. Malignancies
Athenex, Inc.
Phase 1 Unknown
NCT01094288 2019-02-15
A Phase 1 Study of Alisertib Participants With Advanced Solid Tumors Including Castration-Resistant Prostate Cancer Receiving a Standard Docetaxel Regimen
Takeda
Phase 1 Completed
NCT02122770 2019-01-07
Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Participants With Advanced Solid Tumors
Takeda
Phase 1 Completed
NCT00004864 2018-09-10
Docetaxel and GEM 231 in Treating Patients With Recurrent or Refractory Solid Tumors
Montefiore Medical Center
Phase 1 Completed
NCT02490475 2017-05-17
A Multiple-Dose Study of RhuMab 2C4 and Docetaxel in the Treatment of Advanced Solid Tumors
Hoffmann-La Roche
Phase 1 Completed
NCT02274610 2017-05-01
DOPNP201
Samyang Biopharmaceuticals Corporation
Phase 1 Completed
NCT00008125 2016-01-15
Combination Chemotherapy With or Without Filgrastim in Treating Patients With Advanced Solid Tumors
University of Pittsburgh
Phase 1 Completed
NCT01245543 2015-11-02
Safety Study for Intravenous (IV) AC480 (AC480IV) to Treat Advanced Solid Tumors
Daiichi Sankyo
Phase 1 Withdrawn
NCT02120118 2015-06-09
Combination of Hyperthermia and Concurrent Chemoradiotherapy (CCRT) in Treatment Failure Solid Tumors
Shin Kong Wu Ho-Su Memorial Hospital
Phase 2 Withdrawn
NCT01567163 2014-10-16
A Study of Ramucirumab and Docetaxel in Participants With Solid Tumors
Eli Lilly and Company
Phase 2 Completed
NCT01191216 2014-07-24
1-Methyl-D-Tryptophan and Docetaxel in Treating Patients With Metastatic Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00697437 2013-12-10
Effect of Ketoconazole Inhibition of CYP3A on Urinary Excretion of Docetaxel
National University Hospital, Singapore
Phase 2 Completed
NCT01110486 2013-11-06
ABT-348 as Monotherapy or Combination With Carboplatin or Docetaxel to Treat Advanced Solid Tumors
AbbVie
Phase 1 Completed
NCT00045448 2013-05-30
Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00016185 2013-04-05
Flavopiridol and Docetaxel in Treating Patients With Advanced Solid Tumors
Barbara Ann Karmanos Cancer Institute
Phase 1 Completed